| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Ann Thorac Surg 1984;37:371-378
© 1984 The Society of Thoracic Surgeons
Departments of Cardiology, Nuclear Medicine, and Surgery and the Laboratory of Thrombosis and Hemostasis, University of Liège, Medical School, Liège, Belgium
Accepted for publication June 14, 1983.
* Address reprint requests to Dr. Limet, Department of Surgery, University of Liège, 66 Blvd de la Constitution, B.4020, Liège, Belgium
The effects of ticlopidine, a new antiplatelet agent, on graft patency rate was investigated in a group of 150 consecutive patients undergoing aortocoronary bypass graft procedures. In a double-blind study, two groups of 75 patients each received ticlopidine (250 mg twice daily) or a placebo during a three-month period. Graft patency was evaluated by repeat angiography in 38 patients and by rest and stress myocardial scintigraphy in 93. Combined angiographic and scintigraphic analysis was performed in 36 patients. The biological effects of ticlopidine on platelet activity were assessed by bleeding time and appropriate ex vivo tests. Graft patency was evaluated in 131 patients (87%). Evaluation was performed at the end of the three-month therapy period in 77 patients (Groups T1 [ticlopidine] and P1 [placebo]) and five months later in 54 patients. The total graft attrition rate was 10.1% in Group T1 compared with 20.3% in Group P1 (p < 0.1). Excluding patients with discordant biological data, the attrition rate was 7.1% for Group T1 compared with 21.8% for Group P1 (p < 0.02). There was no difference between the subgroups evaluated five months after the end of therapy.
Ticlopidine appears to be an effective means of protecting graft patency as long as the biological effects of the drug are present. This protective effect disappears when the drug is discontinued, which suggests that ticlopidine should be prescribed for a longer period, at least for the first year after operation.
This article has been cited by other articles:
|
|
 |
|
  N. Zimmermann, E. Gams, and T. Hohlfeld Aspirin in coronary artery bypass surgery: new aspects of and alternatives for an old antithrombotic agent Eur J Cardiothorac Surg, July 1, 2008; 34(1): 93 - 108. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. C. Becker, T. W. Meade, P. B. Berger, M. Ezekowitz, C. M. O'Connor, D. A. Vorchheimer, G. H. Guyatt, D. B. Mark, and R. A. Harrington The Primary and Secondary Prevention of Coronary Artery Disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 776S - 814S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. T. Gurbuz, A. A. Zia, A. C. Vuran, H. Cui, and A. Aytac Postoperative clopidogrel improves mid-term outcome after off-pump coronary artery bypass graft surgery: a prospective study Eur J Cardiothorac Surg, February 1, 2006; 29(2): 190 - 195. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. P. Cannon, S. R. Mehta, and S. F. Aranki Balancing the Benefit and Risk of Oral Antiplatelet Agents in Coronary Artery Bypass Surgery Ann. Thorac. Surg., August 1, 2005; 80(2): 768 - 779. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. E. Epstein, J. C. Alexander, D. D. Gutterman, W. Maisel, and J. M. Wharton Anticoagulation: American College of Chest Physicians Guidelines for the Prevention and Management of Postoperative Atrial Fibrillation After Cardiac Surgery Chest, August 1, 2005; 128(2_suppl): 24S - 27S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. D. Stein, H. J. Schunemann, J. E. Dalen, and D. Gutterman Antithrombotic Therapy in Patients With Saphenous Vein and Internal Mammary Artery Bypass Grafts: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 600S - 608S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. L. Bhatt, D. P. Chew, A. T. Hirsch, P. A. Ringleb, W. Hacke, and E. J. Topol Superiority of Clopidogrel Versus Aspirin in Patients With Prior Cardiac Surgery Circulation, January 23, 2001; 103(3): 363 - 368. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. D. Stein, J. E. Dalen, S. Goldman, and P. Theroux Antithrombotic Therapy in Patients With Saphenous Vein and Internal Mammary Artery Bypass Grafts Chest, January 1, 2001; 119(2009): 278S - 282S. [Full Text] [PDF]
|
|
|
|
|
|
J. G. Motwani and E. J. Topol Aortocoronary Saphenous Vein Graft Disease : Pathogenesis, Predisposition, and Prevention Circulation, March 10, 1998; 97(9): 916 - 931. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Collaborative overview of randomised trials of antiplatelet therapy - II: Maintenance of vascular graft or arterial patency by antiplatelet therapy BMJ, January 15, 1994; 308(6922): 159 - 168. [Abstract] [Full Text]
|
|
|
|
|
|
Antiplatelet Trialists Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients BMJ, January 8, 1994; 308(6921): 81 - 106. [Abstract] [Full Text]
|
|
|
|
 |
|
 W. G. Henderson, S. Goldman, J. G. Copeland, T. E. Moritz, and L. A. Harker Antiplatelet or Anticoagulant Therapy after Coronary Artery Bypass Surgery: A Meta-Analysis of Clinical Trials Ann Intern Med, November 1, 1989; 111(9): 743 - 750. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
